These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 24259695)
1. Avanafil for erectile dysfunction. Kyle JA; Brown DA; Hill JK Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738 [TBL] [Abstract][Full Text] [Related]
3. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. Goldstein I; McCullough AR; Jones LA; Hellstrom WJ; Bowden CH; Didonato K; Trask B; Day WW J Sex Med; 2012 Apr; 9(4):1122-33. PubMed ID: 22248153 [TBL] [Abstract][Full Text] [Related]
5. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Limin M; Johnsen N; Hellstrom WJ Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743 [TBL] [Abstract][Full Text] [Related]
6. Avanafil for the treatment of erectile dysfunction. Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913 [TBL] [Abstract][Full Text] [Related]
7. Avanafil for the treatment of erectile dysfunction. An updated review. Egui-Rojo MA; Moncada-Iribarren I; Carballido-RodrÃguez J; MartÃnez-Salamanca JI Arch Esp Urol; 2014 Dec; 67(10):839-47. PubMed ID: 25582903 [TBL] [Abstract][Full Text] [Related]
8. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Belkoff LH; McCullough A; Goldstein I; Jones L; Bowden CH; DiDonato K; Trask B; Day WW Int J Clin Pract; 2013 Apr; 67(4):333-41. PubMed ID: 23521325 [TBL] [Abstract][Full Text] [Related]
9. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Wang H; Yuan J; Hu X; Tao K; Liu J; Hu D Curr Med Res Opin; 2014 Aug; 30(8):1565-71. PubMed ID: 24701971 [TBL] [Abstract][Full Text] [Related]
10. A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction. Park HJ; Kim SW; Kim JJ; Lee SW; Paick JS; Ahn TY; Park K; Park JK; Park NC J Korean Med Sci; 2017 Jun; 32(6):1016-1023. PubMed ID: 28480661 [TBL] [Abstract][Full Text] [Related]
11. Avanafil - a further step to tailoring patient needs and expectations. Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892 [TBL] [Abstract][Full Text] [Related]
13. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. Mochida H; Yano K; Inoue H; Yee S; Noto T; Kikkawa K J Urol; 2013 Aug; 190(2):799-806. PubMed ID: 23321580 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Cui Y; Liu X; Shi L; Gao Z Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196 [TBL] [Abstract][Full Text] [Related]
15. A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice. Mirone V; Fusco F; Parazzini F; Zucchi A Arch Ital Urol Androl; 2016 Jul; 88(2):128-32. PubMed ID: 27377089 [TBL] [Abstract][Full Text] [Related]
16. Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction. Med Lett Drugs Ther; 2014 May; 56(1442):37-8. PubMed ID: 24818838 [No Abstract] [Full Text] [Related]
17. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Alwaal A; Al-Mannie R; Carrier S Drug Des Devel Ther; 2011; 5():435-43. PubMed ID: 22087063 [TBL] [Abstract][Full Text] [Related]
18. Avanafil for the treatment of erectile dysfunction. Segal R; Burnett AL Drugs Today (Barc); 2012 Jan; 48(1):7-15. PubMed ID: 22384456 [TBL] [Abstract][Full Text] [Related]
19. Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Cui YS; Li N; Zong HT; Yan HL; Zhang Y Asian J Androl; 2014; 16(3):472-7. PubMed ID: 24589460 [TBL] [Abstract][Full Text] [Related]
20. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. Mulhall JP; Burnett AL; Wang R; McVary KT; Moul JW; Bowden CH; DiDonato K; Shih W; Day WW J Urol; 2013 Jun; 189(6):2229-36. PubMed ID: 23219537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]